Pontifax Management 4 G.P. (2015) Ltd.

KROS

Pontifax Management 4 G.P. (2015) Ltd. serves as 10% Owner at Keros Therapeutics, Inc. (KROS). This page tracks their complete SEC Form 4 insider trading history including stock purchases and sales.

Total Buys

0 trades

$0.00

Total Sells

1 trades

$84.98M

Net Position

Net Seller

$84.98M

Companies Traded

KROS

Active Period

Oct 2025

1 total trades

Most Recent

Sell KROS

Oct 17, 2025 · $84.98M

Pontifax Management 4 G.P. (2015) Ltd.'s Insider Trading at Keros Therapeutics, Inc. (KROS)

Buys

0 · $0.00

Sells

1 · $84.98M

Total Shares Bought

Total Shares Sold

4,787,331

KROS Price Chart

Loading chart...

Date	Type	Shares	Avg Price	Value	Shares After
Oct 17, 2025	Sell	4,787,331	$17.75	$84.98M	0

Related Insiders

Nima Farzan

director

KROSSell · Jun 8, 2026

Julius Knowles

director

KROSSell · Jun 8, 2026

Seth Alpna

director

KROSSell · Jun 5, 2026

BIENAIME JEAN JACQUES

director

KROSBuy · May 19, 2026

Jasbir Seehra

CHIEF EXECUTIVE OFFICER

KROSSell · Feb 19, 2026

Esther Cho

SVP, General Counsel

KROSSell · Feb 18, 2026

Lorena Raquel Lerner

Chief Science Officer

KROSSell · Feb 18, 2026

Keith Regnante

CHIEF FINANCIAL OFFICER

KROSSell · Feb 18, 2026

Explore More Insider Trading Data

KROS Insider Trading Activity

View all insider trades at Keros Therapeutics, Inc.

Healthcare Sector Insider Trades

See insider activity across healthcare stocks

Latest Insider Buys

Most recent insider purchases across all stocks

CEO Stock Purchases

Track CEO buying activity